Skip to main content
    I

    Inhibikase Therapeutics Inc (IKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.38
    -0.07 (-4.83%)

    Market Cap: $213.21M

    Last updated: Nov 17, 2026 at 4:30 PM ET

    Inhibikase Therapeutics Inc (IKT) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    Inhibikase Therapeutics (IKT) has a latest price of $1.38 on Nov 17, 2026. Its price fell 9.8% over the past 12 months. The month-end price fell 87.0% over the 5 years through Oct 2026, a compound annual decline of 33.5%.

    Price Chart

    From Dec 2020 to Oct 2026, its highest month-end close was $41.39 in Dec 2020 and its lowest $0.89 in Oct 2023, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart IKT with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for IKT.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 43.7%, and over 6 months it fell 12.1%. The month-end price rose 75.0% over the 3 years through Oct 2026, a compound annual rate of 20.5%.

    PeriodChange
    1 month-16.1%
    3 months-43.7%
    6 months-12.1%
    12 months-9.8%
    12 months, with dividends-9.8%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years+75.0%+20.5%
    5 years-87.0%-33.5%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2024, when the price rose 155.9%, and its weakest was 2021, when it fell 78.7%.

    YearCloseChange
    2026 through Oct 2026$1.55-24.4%
    2025$2.05-36.9%
    2024$3.25+155.9%
    2023$1.27-57.7%
    2022$3.00-66.0%
    2021$8.82-78.7%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 25.6% below its 50-day average of $1.85 and 28.5% below its 200-day average of $1.93.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$1.38
    50-day average$1.85-25.6%
    200-day average$1.93-28.5%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 65.2%.

    MeasureValue
    1-year beta1.66
    Largest fall, 1 year-45.2%
    Largest fall, 3 years-65.2%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About IKT

    What is IKT's 1-year price change?

    Inhibikase Therapeutics's price fell 9.8% over the past 12 months. With dividends included, the 12-month total return was -9.8%.

    What is IKT's 5-year price change?

    Inhibikase Therapeutics's month-end price fell 87.0% over the 5 years through Oct 2026, a compound annual decline of 33.5%. These figures leave out dividends.

    What is IKT's beta?

    Inhibikase Therapeutics's 1-year beta against the S&P 500 is 1.66, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 45.2%.

    Is the IKT chart free?

    Yes. Advanced Charting for IKT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.